The German cartel office has approved a deal by Denmark’s Novo Nordisk (NOVOb.CO) to purchase Cardior Pharmaceuticals, the regulator said in a statement on Thursday.
Tag Archive for: cardiovascular disease
Cardior is a leader in the discovery and development of therapies that target RNA as a means to prevent, repair and reverse diseases of the heart. The company’s therapeutic approach targets distinctive non-coding RNAs as a platform for addressing root causes of cardiac dysfunctions with an aim to achieve lasting patient impact.
Following its label expansion earlier this month, Medicare on Thursday said it will now cover the use of Novo Nordisk’s Wegovy in patients with overweight or obesity who have preexisting cardiovascular disease.
On Friday the agency approved a label expansion for Wegovy based on a supplemental New Drug Application for the indication of reducing risks of major adverse cardiovascular events including cardiovascular death, non-fatal heart attack (myocardial infarction) or non-fatal stroke in adults with either overweight or obesity and established cardiovascular disease.
Following the J.P. Morgan Healthcare Conference and other parallel meetings in San Francisco, it’s time to reflect on some of the significant deals secured last week.
Dropping the potential Cytokinetics buy runs contrary to Novartis’ recent dealmaking frenzy, which included the acquisition of Calypso and three research collaborations.
Pharmaceutical executives from Amgen to Pfizer are plotting to break into the lucrative obesity market by developing or cutting deals to acquire better drugs that will compete with Novo Nordisk’s Wegovy and Zepbound from Eli Lilly .
Mergers and acquisitions across the pharmaceuticals and life sciences sector will reach a “healthy” level next year, with deals totaling $225 billion to $275 billion, according to professional services firm PwC’s new US Deals 2024 Outlook report.
Tema ETFs has launched a new exchange traded fund that tracks popular drugmakers like Novo Nordisk and Eli Lilly, aiming to tap into growing demand for their weight-loss and diabetes drugs.
When given at potentially therapeutic doses, Verve’s base editor led to strong reductions in LDL cholesterol and PCSK9 levels in patients with heterozygous familial hypercholesterolemia.